Complete remission, pain intensity, patient and physician evaluation · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
One trial at high risk of bias (de Abreu 2009) compared clofazimine (n=23) with colchicine (n=23). The number with no further aphthous episodes at 6 months was significantly greater in the clofazimine group than the…
1 study · 46 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P=0.015), easily controlled; there was a greater percentage of treatment interruptions in the colchicine group due to…
1 study · 46 participants
GRADE not reported
Complete remission (no further aphthous episodes to 6 months) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
The trial by de Abreu 2009 (high risk of bias) also assessed colchicine (n=23) versus placebo (n=20). The number with no further aphthous episodes at 6 months was not significantly different from placebo (Fisher's…
1 study · 43 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…
1 study · 43 participants
GRADE not reported
Pain at completion of treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Colchicine (0.5 mg per day for 3 months) showed no clear difference in pain at completion of treatment compared with prednisolone (5 mg per day for 3 months); GRADE not reported.
1 finding from 1 review
Number of (minor aphthous) oral ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Colchicine (0.5 mg per day for 3 months) showed no clear difference in number of aphthous ulcers at completion compared with prednisolone (5 mg per day for 3 months); GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Colchicine was associated with statistically significantly more adverse effects than prednisolone (nine participants reporting adverse effects on colchicine versus two on prednisolone).
1 study · 34 participants
GRADE not reported
Recurrence · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Colchicine (0.5 mg per day for 3 months) showed no clear difference in recurrence during treatment period compared with prednisolone (5 mg per day for 3 months); GRADE not reported.
1 finding from 1 review
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg weight-adjusted daily) showed no clear difference in total number of oral ulcers compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in oral ulcer score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg three times daily for 6 months) showed no clear difference in improvement in oral ulcer score compared with placebo; GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review